Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

Authors

  • Tanja Mesti
  • Maja Ebert Moltara
  • Marko Boc
  • Martina Reberšek
  • Janja Ocvirk

Abstract

Background: Treatment options of recurrent malignant glioma are very limited and with a poor survival benefit. Malignant gliomas are highly vascular tumors and represent potentially promising target for anti-vascular endothelial growth factor therapies. Results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial to patients.

Material and methods: We retrospectively reviewed medical documentation of 19 patients with recurrent malignant gliomas treated with bevacizumab and irinotecan. All patients received bevacizumab at 10mg/kg in combination with irinotecan 340mg/m2 or 125mg/m2 (with or without concomitant enzyme inducing antiepileptic drugs, respectively) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated.

Results: We treated 14 (73.7%) man and 5 (26.3%) women. Mean age was 44.7 years (range 27-74). Thirteen patients had glioblastoma multiforme, 5 anaplastic astrocitoma and 1 anaplastic oligoastrocytoma. As an initial therapy all had a standard therapy with primary resection followed by postoperative chemoradiotherapy, except one. WHO performance status range 0-2. In our group average number of chemotherapy applications was 9.3 (range 1-17). Radiological response after 3 months was observed in 9 patients (1 complete response, 8 partial response), seven patients had stable disease and three patients have progressed. The median progression free survival interval was 6.8 months (95%CI: 5.3-8.3); 6 months PFS rate was 52.6%. The median overall survival was 7.7 months (95%CI: 6.6-8.7). Six-month survival rate and twelve-month survival rate were 68.4% and 31.6% respectivelly. There were 16 cases of haematopoetic toxicity, all G1-2. Non-haematopoetic toxicity was present in 14 cases, all G1-2, except one patient with proteinuria G3. No grade 4 toxicities, no trombembolic event and no intracranial hemorrhage were observed.

Conclusion: The combination of bevacizumab and irinotecan is an active regimen with acceptable toxicity in malignant glioma patients. Comparison of progression free survival and survival rates with historical data indicate a trend to better survival, still randomized controlled trials are needed to confirm any survival benefit.

Author Biographies

Tanja Mesti

Maja Ebert Moltara

Marko Boc

Martina Reberšek

Janja Ocvirk

Downloads

Published

2015-02-11

How to Cite

Mesti, T., Ebert Moltara, M., Boc, M., Reberšek, M., & Ocvirk, J. (2015). Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiology and Oncology, 49(1). Retrieved from https://www.radioloncol.com/index.php/ro/article/view/2010

Issue

Section

Clinical oncology